Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd > UCSF - Medical Center
View:
Post by Trippedstocks on Feb 13, 2021 11:10am

UCSF - Medical Center

Dr. Fahy began working with RVV on Dec. 31, 2020. San Francisco had over 200 Hospitalized cases of Covid-19. Two weeks later there was about 160. On Jan 29 there was 122. At that same time there was about 50 cases in ICU with the larger ICU being at UCSF. On Jan 29. 20 in ICU at UCSF medical center. As well there would be 30 additional hospitalized patients at UCSF. Who is in charge of patient care in ICU at UCSF and would have significant influence (in the bay area) in standard care of hospitalized Covid-19 patients, not just at UCSF?

q "Dr. John Fahy, MD, MSc is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Department of Medicine at the University of California San Francisco and is a director of UCSFs severe asthma clinic. He also cares for critically ill patients in the intensive care units and directs the UCSF Airway Clinical Research Center."

Now with his known thiol research, he would most likely be willing to give a thiol drug to a patient. What drug and company have a IND EAP for a thiol drug? Dr. Fahy isn't just reviewing the clinical results, he IS the EAP.

Am I connecting dots?

https://www.latimes.com/projects/california-coronavirus-cases-tracking-outbreak/san-francisco-county/
Comment by Chrisxd5 on Feb 13, 2021 11:26am
If these dots are correct then we are golden!!! 
Comment by rickydee on Feb 13, 2021 11:37am
This post has been removed in accordance with Community Policy
Comment by Trippedstocks on Feb 13, 2021 11:45am
It all clicked last night. Trial is slower than expected. They hire a doctor to basically prescribe Buci at UCSF. Knowing the Dr has research that proves thiol-based drugs like Bucillamine act as an antiviral. They provide top line results from EAP for severe hospitalized patients and soon after, pier reviewed results. That gets mainstream coverage. That would fill the ph 3 real quick, which they ...more  
Comment by alwaysoff on Feb 13, 2021 12:30pm
Totally awesome DD. Your post makes total sense. Onwards and upwards folks. Next few months are going to be very interesting. GLTA  
Comment by 1ottrunner on Feb 13, 2021 3:04pm
Not a bad line of thinking, a stretch but a possibility.  RVV would not have to complete the trial if the above turned out to be factual, even 10% would likely get it quickly through the FDA.  The safety is proven.
Comment by Trippedstocks on Feb 13, 2021 5:28pm
yes, it may be a stretch, but the big stretch is people thinking phase 3 results are coming tomorrow, or the day after, maybe Tuesday.... No Jan 25, no after the bought deal.... The companies investors deck is showing this to be Q1-2021. I think the company knows what quarter they are in. I don't care that they filed year end in June, that was pandemic delay on reporting and wouldn't ...more  
Comment by Chrisxd5 on Feb 13, 2021 6:26pm
I DONT LIKE YOU ANYMORE!  Unless your wrong then ok
Comment by Chrisxd5 on Feb 13, 2021 6:28pm
You ignoring this:  The Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization.
Comment by Trippedstocks on Feb 13, 2021 6:39pm
it will meet it's enrollment number goals. Again what do they mean by pace? They have not meet estimated trial timelines. they said in October "it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020." And we know the trial started late, Nov27. They were wrong on their estimate then. did they add more sites because ...more  
Comment by Chrisxd5 on Feb 13, 2021 6:43pm
I doubt that.  Money was a issue but they were finishing up first interim.  Needed more sites because overwhelmed with patients and then needed money "canacord" to help finance additional sites and complete up to 1000 patients. I think we will be hearing something sooner than you think.  Again I could be wrong but from what I'm hearing it will be very soon 
Comment by Trippedstocks on Feb 13, 2021 7:07pm
estimated cost of Bucillamine ph 3 is $25 million. We have another $6 million allocated. There will be another bought deal/whatever again in the future. Yes unless grants and funding and buy out etc... you need to read the prospectus not just what you hear. Am I even right on my cut and paste quotes? DD bud :) been long a year now. I know the stuff works. There used to be more DD on the internet ...more